Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of clinical pharmacology

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270008329556PMID 19179295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

  2008cited by this paper
• An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

  2008cited by this paper
• Immunoglobulins: Structure and Function

  2008cited by this paper
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

  2008cited by this paper
• A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

  2007cited by this paper
• Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development

  2007cited by this paper
• Development, cytokine profile and function of human interleukin 17–producing helper T cells

  2007cited by this paper
• A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

  2007cited by this paper
• Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check

  2007cited by this paper
• Elimination mechanisms of therapeutic monoclonal antibodies.

  2006cited by this paper
• Population‐Based Assessments of Clinical Drug‐Drug Interactions: Qualitative Indices or Quantitative Measures?

  2006cited by this paper
• IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis

  2006cited by this paper
• Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

  2005cited by this paper
• The comorbid state of psoriasis patients in a university dermatology practice

  2005cited by this paper
• Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti‐CD11a Antibody) Following Long‐Term Subcutaneous Weekly Dosing in Psoriasis Subjects

  2005cited by this paper
• Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.

  2005cited by this paper
• IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

  2005cited by this paper
• Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia

  2005cited by this paper
• A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.

  2004cited by this paper
• Pharmacokinetics of a human monoclonal antibody to IL‐12 P40 following single intravenous infusion in patients with moderate to severe plaque‐type psoriasis

  2004cited by this paper
• Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis

  2004cited by this paper
• Antibody pharmacokinetics and pharmacodynamics.

  2004cited by this paper
• Interleukin-12 and the regulation of innate resistance and adaptive immunity

  2003cited by this paper
• Disease concomitance in psoriasis: a clinical study of 61 cases.

  2001cited by this paper
• A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

  1999cited by this paper
• Changes in capillary permeability in diabetic patients

  1997cited by this paper
• Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells

  1997cited by this paper
• Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

  1996cited by this paper
• Epidemiology of psoriasis: clinical issues.

  1994cited by this paper
• Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.

  1994cited by this paper
• Glycation increases the vascular clearance rate of IgG in mice

  1993cited by this paper
• Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

  1992cited by this paper
• Transcapillary colloid osmotic gradient, plasma volume and interstitial fluid volume in long-term Type 1 (insulin-dependent) diabetes

  1985cited by this paper
• The transmission of immunity from mother to young and the catabolism of immunoglobulins.

  1966cited by this paper

• Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS)

  2025cites this paper
• Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice

  2025cites this paper
• Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

  2025cites this paper
• A novel nomogram based on clinical features and laboratory parameters to predict biologic-refractory psoriasis patients.

  2025cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2025influential citation
• A Semi-Mechanistic Mathematical Model of Immune Tolerance Induction to Support Preclinical Studies of Human Monoclonal Antibodies in Rats

  2025influential citation
• Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities

  2024cites this paper
• Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension

  2024cites this paper
• Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis

  2024influential citation
• Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

  2024cites this paper
• Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial

  2023cites this paper
• Assessing developability early in the discovery process for novel biologics

  2023cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2023cites this paper
• [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2----Management of Special Populations, Patients With Comorbid Conditions, and Risk

  2023cites this paper
• Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis

  2022cites this paper
• Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects

  2022cites this paper
• Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

  2022influential citation
• Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain

  2022cites this paper
• Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.

  2022cites this paper
• Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade

  2022cites this paper
• Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life

  2022cites this paper
• Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies

  2022cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2022cites this paper
• Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.

  2022cites this paper
• Interleukin 12/23 Inhibitors

  2021cites this paper
• Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis

  2021cites this paper
• Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint

  2021cites this paper
• Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

  2021cites this paper
• Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes

  2021cites this paper
• Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model

  2021cites this paper
• New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab

  2021cites this paper
• Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease

  2021influential citation
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2021cites this paper
• Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

  2020influential citation
• Ustekinumab

  2020cites this paper
• Psoriasis and Comorbidities

  2020cites this paper
• Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

  2020cites this paper
• Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection

  2020cites this paper
• Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications

  2020cites this paper
• Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

  2020cites this paper
• Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

  2020cites this paper
• Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection

  2020cites this paper
• Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real‐world practice

  2020cites this paper
• Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents

  2020cites this paper
• Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data

  2020cites this paper
• Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

  2020cites this paper
• Obesity and its role in the management of rheumatoid and psoriatic arthritis

  2020cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2020cites this paper
• Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease

  2019cites this paper
• Understanding Inter-Individual Variability in Monoclonal Antibody Disposition

  2019cites this paper
• Monoclonal Antibodies: From Structure to Therapeutic Application

  2019cites this paper
• Utility of Joint Population Exposure-Response Modeling Approach to Assess Multiple Continuous and Categorical Endpoints in Immunology Drug Development

  2019cites this paper
• Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review

  2019cites this paper
• Characteristics of biological therapy in pediatric patients with Crohn’s disease

  2019cites this paper
• The pharmacological management of patients with comorbid psoriasis and obesity

  2019cites this paper
• Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies

  2019cites this paper
• Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis.

  2019cites this paper
• Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

  2019cites this paper
• Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.

  2019cites this paper
• An investigation into the association and prediction of serious infection in patients on biologic therapies for psoriasis

  2019cites this paper
• Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus - Belimumab

  2019cites this paper
• Pharmacokinetics and C‐reactive protein modelling of anti‐interleukin‐6 antibody (PF‐04236921) in healthy volunteers and patients with autoimmune disease

  2018cites this paper
• Population Pharmacokinetics of the TNF‐α and IL‐17A Dual‐Variable Domain Antibody ABT‐122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials

  2018cites this paper
• Mechanism of Action and Pharmacokinetics of Biologics

  2018cites this paper
• Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

  2018cites this paper
• Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

  2018cites this paper
• Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

  2018cites this paper
• Large molecules with large pharmacokinetic variability: progress in pursuit of key considerations for intersubject variability

  2018cites this paper
• Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin‐6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

  2018cites this paper
• Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.

  2018cites this paper
• Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review

  2018cites this paper
• Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

  2018cites this paper
• Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

  2018cites this paper
• Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

  2018cites this paper
• Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

  2018cites this paper
• Why Use TDM and Dashboards for Monoclonal Antibodies? The Promise of Individualized Therapy

  2017cites this paper
• Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease

  2017cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2017cites this paper
• Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa

  2017cites this paper
• Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

  2017cites this paper
• Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era.

  2017cites this paper
• Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

  2017cites this paper
• Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain

  2016cites this paper
• Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

  2016influential citation
• Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy

  2016cites this paper
• Considerations for Systemic Treatment of Psoriasis in Obese Patients

  2016cites this paper
• Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies

  2016cites this paper
• Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.

  2015cites this paper
• A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life

  2015cites this paper
• Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn's Disease: Results from a Randomized, Multicenter, Phase-3 Study

  2015cites this paper
• Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR

  2015cites this paper
• Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

  2015cites this paper
• Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

  2015cites this paper
• Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics

  2015cites this paper
• PK-PD Analysis of PASI with Data at Boundary: BI 655066 an Anti-IL-23A mAb for the Treatment of Psoriasis

  2015cites this paper
• Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative

  2015cites this paper
• Utility of population pharmacokinetic modeling in the assessment of therapeutic protein‐drug interactions

  2014cites this paper
• Investigation of the Influence of Nephropathy on Monoclonal Antibody Disposition: A Pharmacokinetic Study in a Mouse Model of Diabetic Nephropathy

  2014cites this paper
• Psoriasis and Comorbidities

  2014cites this paper